News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cancer Trials Show One Year on Roche (RHHBY)'s Herceptin is Best



10/1/2012 7:39:47 AM

ZURICH--Roche Holding AG (ROG.VX) and the Breast International Group Monday announced final results from the Phase III HERA trial, which confirmed that one year of Herceptin (trastuzumab) treatment remains the standard of care for people with early-stage HER2-positive breast cancer.

MAIN FACTS:

- These data showed that there was no difference in the time women lived without their disease returning (disease-free survival) when they received Herceptin for two years versus one year, a secondary endpoint of the study.

- After a median follow-up of eight years, the improvements in disease-free survival and overall survival for women who received Herceptin for one year remained statistically significant compared to women who underwent observation alone.

- There were no new safety findings in the study

-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com


Read at BioSpace.com


comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES